home / stock / oncy / oncy quote
Last: | $1.06 |
---|---|
Change Percent: | 0.0% |
Open: | $1.04 |
Close: | $1.06 |
High: | $1.06 |
Low: | $1.01 |
Volume: | 294,224 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.06 | $1.04 | $1.06 | $1.06 | $1.01 | 294,224 | 03-29-2024 |
$1.06 | $1.04 | $1.06 | $1.06 | $1.01 | 294,183 | 03-28-2024 |
$1.03 | $1.03 | $1.03 | $1.03 | $1 | 132,081 | 03-27-2024 |
$1.01 | $1.03 | $1.01 | $1.03 | $1.0001 | 105,522 | 03-26-2024 |
$1.03 | $1.02 | $1.03 | $1.03 | $1.0095 | 182,822 | 03-25-2024 |
$1 | $1.01 | $1 | $1.02 | $1 | 125,298 | 03-22-2024 |
$1.03 | $1.02 | $1.03 | $1.03 | $1.01 | 106,863 | 03-21-2024 |
$1.01 | $1.01 | $1.01 | $1.03 | $1 | 90,720 | 03-20-2024 |
$1.03 | $1.02 | $1.03 | $1.03 | $1 | 132,968 | 03-19-2024 |
$1.04 | $0.9829 | $1.04 | $1.05 | $0.97 | 327,349 | 03-18-2024 |
$0.9889 | $1 | $0.9889 | $1.02 | $0.97 | 399,134 | 03-15-2024 |
$1.02 | $1.03 | $1.02 | $1.04 | $1 | 229,620 | 03-14-2024 |
$1.04 | $1.04 | $1.04 | $1.06 | $1.02 | 165,167 | 03-13-2024 |
$1.06 | $1.07 | $1.06 | $1.07 | $1.02 | 148,649 | 03-12-2024 |
$1.06 | $1.06 | $1.06 | $1.08 | $1.01 | 186,970 | 03-11-2024 |
$1.05 | $1.07 | $1.05 | $1.12 | $1.01 | 426,265 | 03-08-2024 |
$1.04 | $1.02 | $1.04 | $1.08 | $1.0013 | 418,360 | 03-07-2024 |
$1.04 | $1.02 | $1.04 | $1.04 | $0.9877 | 259,065 | 03-06-2024 |
$1.03 | $0.98 | $1.03 | $1.04 | $0.96 | 427,792 | 03-05-2024 |
$0.92 | $1.16 | $0.92 | $1.16 | $0.8855 | 1,752,448 | 03-04-2024 |
News, Short Squeeze, Breakout and More Instantly...
Oncolytics Biotech Inc. Company Name:
ONCY Stock Symbol:
NASDAQ Market:
Oncolytics Biotech Inc. Website:
USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Rec...
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights Canada NewsWire Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combina...
Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...